WO1996012009A3 - Methods for engineering antigen-presenting cells - Google Patents

Methods for engineering antigen-presenting cells Download PDF

Info

Publication number
WO1996012009A3
WO1996012009A3 PCT/US1995/012718 US9512718W WO9612009A3 WO 1996012009 A3 WO1996012009 A3 WO 1996012009A3 US 9512718 W US9512718 W US 9512718W WO 9612009 A3 WO9612009 A3 WO 9612009A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
presenting cells
engineering antigen
antigen
engineering
Prior art date
Application number
PCT/US1995/012718
Other languages
French (fr)
Other versions
WO1996012009A2 (en
Inventor
Mark L Tykocinski
Original Assignee
Mark L Tykocinski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark L Tykocinski filed Critical Mark L Tykocinski
Publication of WO1996012009A2 publication Critical patent/WO1996012009A2/en
Publication of WO1996012009A3 publication Critical patent/WO1996012009A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A protein transfer method for producing a cell having a defined MHC: nominal antigen peptide or costimulator on its membrane.
PCT/US1995/012718 1994-10-14 1995-10-11 Methods for engineering antigen-presenting cells WO1996012009A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32412594A 1994-10-14 1994-10-14
US08/324,125 1994-10-14

Publications (2)

Publication Number Publication Date
WO1996012009A2 WO1996012009A2 (en) 1996-04-25
WO1996012009A3 true WO1996012009A3 (en) 1996-10-10

Family

ID=23262194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012718 WO1996012009A2 (en) 1994-10-14 1995-10-11 Methods for engineering antigen-presenting cells

Country Status (1)

Country Link
WO (1) WO1996012009A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5006998B2 (en) * 1996-05-23 2012-08-22 ザ スクリプス リサーチ インスティチュート MHC class II antigen presentation system and CD4 + T cell activation method
US6440736B1 (en) * 1998-10-16 2002-08-27 U-Bisys B.V. Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules
EP1001017A1 (en) * 1998-10-16 2000-05-17 U-BISys B.V. Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules
JP2002532514A (en) * 1998-12-14 2002-10-02 デンドレオン コーポレイション Compositions and methods for enhancing major histocompatibility complex class I restricted antigen presentation
US7148324B1 (en) 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
D. BROWN ET AL.: "GPI-anchored membrane proteins", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 3, no. 4, 1992, pages 895 - 906, XP002009547 *
HUANG, J.-H. ET AL.: "Expression and functional analysis of a recombinant human GPI anchored class I human leukocyte", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. Suppl. 16D, 1992, pages 64 - abstract O 424, XP002009545 *
HUANG, J.-H. ET AL.: "Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis", IMMUNITY, vol. 1, 1994, pages 607 - 613, XP002009544 *
HUANG, J.-H. ET AL: "Alloantigenic recognition of artificial GPI-anchored HLA-A2.1", MOLECULAR IMMUNOLOGY, vol. 31, no. 13, 1994, pages 1017 - 1028, XP002009546 *
P. PAGLIA ET AL.: "Immortalized dendritic cell line fully competent in antigen presentation initiates primary T cell responses in vivo", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 178, 1993, pages 1893 - 1901, XP002009550 *
P. TABACZEWSKI ET AL.: "Expression of secreted and GPI-bound Qa-2 molecules is dependent on functional TAP-2 peptide transporter", JORNAL OF IMMUNOLGY, vol. 152, no. 11, 1994, pages 5268 - 5274, XP002009548 *
R. GREENLAW ET AL.: "Transfection of HLA-DR-expressing DAP.3 cells with a cDNA clone encoding the GPI-linked form of LAF-3: biochemical features and functional consequences", INTERNATIONAL IMMUNOLGY, vol. 4, no. 6, 1992, pages 673 - 680, XP002009549 *
S. D. NORTON ET AL.: "The CD28 lignad, B7, enhances IL-2 production by providing costimulatory signal to T cells", JOURNAL OF IMMUNOLOGY, vol. 149, no. 5, 1992, pages 1556 - 1561, XP002009551 *

Also Published As

Publication number Publication date
WO1996012009A2 (en) 1996-04-25

Similar Documents

Publication Publication Date Title
HK1015960A1 (en) Surface replica fuel cell having a fiber-reinforced membrane.
GB2330836B (en) Solid polyelectrolyte membrane for fuel cells,and method for producing it
AU2821095A (en) Processes for producing low cost, high efficiency silicon solar cells
ZA964776B (en) Mammalian cell culture process.
AU2451297A (en) Artifical chromosomes, uses thereof and methods for preparing artificial chromosomes
AU660404B3 (en) Solar power system
AU5807296A (en) Temperature regulating system for a fuel cell powered vehicl e
AU4818599A (en) Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12),md-1, md2 and cyclin e2, related reagents and methods
AU4455797A (en) Method for producing microporous elements, the microporous elements thus produced and uses thereof
AU4451597A (en) An electrolyte system, a method for the preparation thereof, the use thereof and a battery containing the electrolyte system
AU8063798A (en) Secretory immunoglobulin produced by single cells and methods for making and using same
EP0773993A4 (en) Genetically engineered swine cells
EP0727482A3 (en) Process for the culture of cells on a support, device therefor and utilisation of said device
AU5893296A (en) Solar cell system and method of establishing the system
AU7209496A (en) Method for making an electrochemical cell, and resulting electrochemical cell
AU5789499A (en) (neisseria meningitidis) polypeptide, nucleic acid sequence and uses thereof
AU7327396A (en) Method for preparing a cylindrical separator, a tool usable for the method and a cylindrical cell with the separator
AU1025897A (en) Solar cell contacting scheme
AU2667995A (en) Chimerical peptide-nucleic acid fragment, process for producing the same and its use for appropriately introducing nucleic acids into cell organelles and cells
WO1996012009A3 (en) Methods for engineering antigen-presenting cells
AU6330596A (en) Current collectors for alkaline cells
EP1083617A3 (en) Method for operating a fuel cell system and device for carrying out the method
EP1170811A3 (en) Fuel cell system and method for operating the system
AU8883798A (en) A process for repairing membrane imperfections
WO1998032863A3 (en) Mammalian thioredoxin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase